Meeting
2014 Palliative and Supportive Care in Oncology Symposium
Evaluation of nausea control with NEPA, a novel oral combination antiemetic.
Authors
Snezana Bosnjak
Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
Snezana Bosnjak, Lee Steven Schwartzberg, Giada Rizzi, Maria Elisa Borroni
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: End-of-Life Care, <span>Patient-Reported Outcomes</span>, and Survivorship
Track
Survivorship,Patient-Reported Outcomes: Mechanisms of Symptoms and Treatment Toxicities,Early Integration of Palliative Care in Cancer Care,Psycho-oncology,End-of-Life Care
Sub Track
Patient-Reported Outcomes: Mechanisms of Symptoms and Treatment Toxicities
Clinical Trial Registration Number
NCT01339260; NCT01376297
Citation
J Clin Oncol 32, 2014 (suppl 31; abstr 169)
DOI
10.1200/jco.2014.32.31_suppl.169
Abstract #
169
Poster Bd #
E2
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Quality Care Symposium
Impact on patients’ daily life activities of NEPA, the oral fixed-dose combination of netupitant, a new NK1 receptor antagonist (RA), and palonosetron (PALO) plus dexamethasone (DEX) versus PALO plus DEX for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC).
First Author: Matti S. Aapro
Poster
2013 ASCO Annual Meeting
Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).
First Author: Matti S. Aapro
Poster
2023 ASCO Annual Meeting
A phase III, double-blind, non-inferiority, randomized controlled trial of antiemetic prophylaxis for highly emetogenic chemotherapy without dexamethasone: CINV POD study.
First Author: Venkatraman Radhakrishnan
Poster
2022 ASCO Annual Meeting
Olanzapine with or without an NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy: A phase III randomized, double-blind, placebo-controlled trial (ALLIANCE A221602).
First Author: Rudolph M. Navari